The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Real world outcomes of high-grade lymphoma treated with CD19 CAR-T in England
England was one of the first European countries that granted fully funded access to CD19 CAR-T therapies. CAR-T products are available through the National Health Service England (NHSE) and CAR-T slots are approved by a weekly National CAR-T Clinical Panel (NCCP). Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the real world data on the first 122 lymphoma patients who received treatment with CD19 CAR-T therapies. Dr Collins highlights the importance of identifying CAR-T responders. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
